Related Experiment Video

Updated: Jul 13, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Biologics in Crohn's disease: searching indicators for outcome

C Janneke van der Woude1, Daniel W Hommes

  • 1Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands. c.vanderwoude@erasmusmc.nl

Expert Opinion on Biological Therapy
|August 21, 2007
PubMed

Insights

New biologic therapies for Crohn's disease (a chronic inflammatory bowel disease) are emerging. This review examines their efficacy, safety, and indicators for use, highlighting the need for better predictive markers.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Crohn's disease pathogenesis insights drive novel therapeutic development.
  • Existing biologic drug mechanisms are well-studied, but clinical implementation requires better predictive indicators.
  • Biologics represent a significant advancement in managing Crohn's disease.

Purpose of the Study:

  • To review current biologic therapies for Crohn's disease.
  • To focus on efficacy, steroid-sparing effects, mucosal healing, and safety profiles.
  • To discuss the role of immunogenicity in biologic treatment response.

Main Methods:

  • Systematic literature review of clinical trials and observational studies.
  • Analysis of efficacy data, including clinical remission and response rates.
  • Evaluation of safety data, adverse events, and immunogenicity assessments.

Main Results:

  • Biologics demonstrate significant efficacy in inducing and maintaining remission in Crohn's disease.
  • Many biologics offer steroid-sparing benefits, reducing corticosteroid-related side effects.
  • Mucosal healing is a key outcome, associated with improved long-term prognosis.
  • Immunogenicity can impact long-term efficacy and safety, necessitating monitoring.

Conclusions:

  • Biologic therapies have transformed Crohn's disease management.
  • Further research is needed to identify reliable biomarkers for predicting treatment response and optimizing biologic selection.
  • Personalized medicine approaches are crucial for maximizing therapeutic benefits and minimizing risks in Crohn's disease patients.

More Related Videos

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...